HRP20201261T1 - Spojevi tiazolidina za liječenje virusnih infekcija - Google Patents
Spojevi tiazolidina za liječenje virusnih infekcija Download PDFInfo
- Publication number
- HRP20201261T1 HRP20201261T1 HRP20201261TT HRP20201261T HRP20201261T1 HR P20201261 T1 HRP20201261 T1 HR P20201261T1 HR P20201261T T HRP20201261T T HR P20201261TT HR P20201261 T HRP20201261 T HR P20201261T HR P20201261 T1 HRP20201261 T1 HR P20201261T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- symptom
- pharmaceutical preparation
- disease
- condition
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- 206010011224 Cough Diseases 0.000 claims 4
- 206010019233 Headaches Diseases 0.000 claims 4
- 208000000112 Myalgia Diseases 0.000 claims 4
- 206010028735 Nasal congestion Diseases 0.000 claims 4
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 4
- 201000007100 Pharyngitis Diseases 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 206010016256 fatigue Diseases 0.000 claims 4
- 231100000869 headache Toxicity 0.000 claims 4
- 241000709661 Enterovirus Species 0.000 claims 3
- 206010060891 General symptom Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical group OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical group CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims 1
- CAYJBRBGZBCZKO-BHGBQCOSSA-N ethyl (e,4s)-4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate Chemical compound C([C@@H](/C=C/C(=O)OCC)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)C1=NOC(C)=C1)C(C)C)CC=1C=CC(F)=CC=1)[C@@H]1CCNC1=O CAYJBRBGZBCZKO-BHGBQCOSSA-N 0.000 claims 1
- 208000021760 high fever Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002480 nitazoxanide Drugs 0.000 claims 1
- 229950007656 rupintrivir Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. Farmaceutski pripravak koji sadrži najmanje jedan nitazoksanid ili tizoksanid ili njegovu farmaceutski prihvatljivu sol za uporabu u postupku liječenja bolesti ili stanja uzrokovanog ili povezanog s virusom koji pripada obitelji Picornaviridae, naznačen time što navedeni postupak uključuje davanje subjektu u potrebi za tim terapeutski učinkovite količine navedenog farmaceutskog pripravka.
2. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što virus pripada rodu Enterovirus.
3. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što navedeno davanje ublažava barem jedan simptom bolesti ili stanja, pri čemu je najmanje jedan simptom odabran između groznice, kašlja, grlobolje, začepljenja nosa, umora, glavobolje, mijalgije i visoke temperature.
4. Farmaceutski pripravak za uporabu prema zahtjevu 3, naznačen time što navedeno davanje a) smanjuje temperaturu uzrokovanu ili povezanu s bolešću ili stanjem i b) ublažava barem jedan simptom bolesti ili stanja, pri čemu je najmanje jedan simptom odabran između kašlja, grlobolje, začepljenja nosa, umora, glavobolje, mijalgije i visoke temperature.
5. Farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time što davanje a) smanjuje temperaturu uzrokovanu ili povezanu s bolešću ili stanjem, i b) ublažava barem jedan respiratorni simptom uzrokovan ili povezan s bolešću ili stanjem i najmanje jedan opći simptom povezan s bolešću ili stanjem, pri čemu je najmanje jedan respiratorni simptom odabran između kašlja, grlobolje, i začepljenosti nosa i pri čemu je najmanje opći simptom odabran između umora, glavobolje, mialgije i visoke temperature.
6. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što se virus bira između enterovirusa A-J.
7. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što se virus bira između rinovirusa A-C.
8. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što nadalje sadrži davanje subjektu terapeutski učinkovite količine antivirusnog sredstva direktnog djelovanja.
9. Farmaceutski pripravak za uporabu prema zahtjevu 8, naznačen time što antivirusno sredstvo direktnog djelovanja je rupintrivir ili MK-0608 ili njegova farmaceutski prihvatljiva sol.
10. Farmaceutski pripravak za uporabu prema zahtjevu 2, naznačen time što navedeno davanje započinje u roku od 48 sati od pojave kod subjekta barem jednog simptoma bolesti ili stanja, pri čemu je najmanje jedan simptom odabran između groznice, kašlja, upale grla, začepljenosti nosa, umora, glavobolje, mialgije i visoke temperature.
11. Farmaceutski pripravak za uporabu prema zahtjevu 1, naznačen time što je subjekt čovjek.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316463P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/024976 WO2017173056A1 (en) | 2016-03-31 | 2017-03-30 | Thiazolide compounds for treating viral infections |
| EP17716741.8A EP3436074B1 (en) | 2016-03-31 | 2017-03-30 | Thiazolide compounds for treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201261T1 true HRP20201261T1 (hr) | 2021-02-05 |
Family
ID=58530692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201261TT HRP20201261T1 (hr) | 2016-03-31 | 2020-08-11 | Spojevi tiazolidina za liječenje virusnih infekcija |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11135202B2 (hr) |
| EP (2) | EP3677282A1 (hr) |
| JP (2) | JP6567781B2 (hr) |
| KR (3) | KR102136803B1 (hr) |
| CN (1) | CN108289961A (hr) |
| AU (2) | AU2017244145B2 (hr) |
| BR (1) | BR112018069974A2 (hr) |
| CA (2) | CA3019326C (hr) |
| CY (1) | CY1123221T1 (hr) |
| DK (1) | DK3436074T3 (hr) |
| EA (2) | EA202091849A1 (hr) |
| ES (1) | ES2810303T3 (hr) |
| HK (1) | HK1250945A1 (hr) |
| HR (1) | HRP20201261T1 (hr) |
| HU (1) | HUE050601T2 (hr) |
| IL (2) | IL262018A (hr) |
| LT (1) | LT3436074T (hr) |
| MX (1) | MX2021004464A (hr) |
| PH (1) | PH12018502058A1 (hr) |
| PL (1) | PL3436074T3 (hr) |
| PT (1) | PT3436074T (hr) |
| SG (1) | SG11201808453UA (hr) |
| SI (1) | SI3436074T1 (hr) |
| UA (1) | UA126114C2 (hr) |
| WO (1) | WO2017173056A1 (hr) |
| ZA (1) | ZA201806644B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111012778B (zh) * | 2018-10-10 | 2022-06-24 | 北京市农林科学院 | Nitazoxanide在抑制犬细小病毒中的应用 |
| CN109536460A (zh) * | 2018-12-07 | 2019-03-29 | 中国医学科学院医学生物学研究所 | 一种cv-a10病毒毒种及其人用灭活疫苗 |
| CN110787161B (zh) * | 2019-09-19 | 2022-09-27 | 中山大学 | 噻唑类化合物用于抗鱼类病毒的新用途 |
| CN111012788B (zh) * | 2019-12-12 | 2021-01-15 | 武汉职业技术学院 | 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用 |
| WO2022020243A1 (en) * | 2020-07-20 | 2022-01-27 | Romark Laboratories L.C. | Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine |
| AU2021333566A1 (en) | 2020-08-24 | 2023-03-16 | Romark Laboratories L.C. | Use of thiazolides against coronaviruses |
| CA3219500A1 (en) * | 2021-05-28 | 2022-12-01 | Theodore HENDERSON | Treatment using an antiviral compound and nitazoxanide |
| TW202327621A (zh) | 2021-09-15 | 2023-07-16 | 大陸商南京強新生物醫藥有限公司 | 治療冠狀病毒感染的新聯用藥物、藥物組合物及其用途 |
| CN114404439B (zh) * | 2022-02-11 | 2023-07-11 | 山东农业大学 | 抑制不同类型猪繁殖与呼吸综合症病毒感染的阻断剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| US5387598A (en) | 1994-04-13 | 1995-02-07 | Rossignol; Jean-Francois | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
| MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| US5859038A (en) | 1994-09-08 | 1999-01-12 | Romark Laboratories, L.C. | Method for treatment of helicobacter pylori infections |
| US5856348A (en) | 1994-09-08 | 1999-01-05 | Romark Laboratories, L.C. | Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5965590A (en) | 1994-09-08 | 1999-10-12 | Romark Lab Lc | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5935591A (en) | 1998-01-15 | 1999-08-10 | Romark Laboratories, L.C. | Method for treatment of equine protozoal myeloencephalitis with thiazolides |
| AU2004229527B2 (en) | 2003-04-11 | 2009-08-20 | Medimmune, Llc | Methods of preventing or treating respiratory conditions |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| US20060194853A1 (en) | 2004-10-08 | 2006-08-31 | Rossignol Jean F | Alkyl benzamides |
| MX2008008723A (es) | 2006-01-09 | 2008-09-26 | Romark Lab Lc | Tratamiento de la hepatitis viral. |
| JP5676258B2 (ja) | 2007-08-03 | 2015-02-25 | ロマーク ラボラトリース，エル．シー． | アルキルスルホニル置換チアゾリド化合物 |
| GB0716292D0 (en) * | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| US8524278B2 (en) | 2009-02-13 | 2013-09-03 | Romark Laboratories L.C. | Controlled release pharmaceutical formulations of nitazoxanide |
| JP5918124B2 (ja) | 2009-05-12 | 2016-05-18 | ロマーク ラボラトリーズ エル．シー． | ハロアルキルヘテロアリールベンズアミド化合物 |
| MX341877B (es) * | 2009-06-26 | 2016-09-06 | Romark Laboratories L C * | Compuestos y métodos para tratar influenza. |
| EP2585067B1 (en) * | 2010-06-25 | 2017-08-09 | Biota Scientific Management Pty Ltd | Compound for the treatment of enteroviruses |
| CN103269593A (zh) | 2010-11-01 | 2013-08-28 | 罗马克实验室有限公司 | 烷基亚磺酰基取代的噻唑化物化合物 |
| BR112013029505A2 (pt) | 2011-05-16 | 2020-01-07 | Romark Laboratories L.C. | Composição farmacêutica, e, uso de um composto |
| JP5904270B2 (ja) | 2012-03-15 | 2016-04-13 | トヨタ自動車株式会社 | 車両走行制御装置 |
| SG10201804835VA (en) * | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US10328128B2 (en) * | 2014-09-17 | 2019-06-25 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus D68 |
| JP6633092B2 (ja) | 2014-11-11 | 2020-01-22 | ロマーク ラボラトリーズ，リミティド カンパニー | チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法 |
-
2017
- 2017-03-30 PT PT177167418T patent/PT3436074T/pt unknown
- 2017-03-30 BR BR112018069974A patent/BR112018069974A2/pt not_active Application Discontinuation
- 2017-03-30 UA UAA201809863A patent/UA126114C2/uk unknown
- 2017-03-30 KR KR1020187030521A patent/KR102136803B1/ko active IP Right Grant
- 2017-03-30 PL PL17716741T patent/PL3436074T3/pl unknown
- 2017-03-30 CA CA3019326A patent/CA3019326C/en active Active
- 2017-03-30 EA EA202091849A patent/EA202091849A1/ru unknown
- 2017-03-30 CA CA3113354A patent/CA3113354A1/en not_active Abandoned
- 2017-03-30 KR KR1020187030535A patent/KR102233826B1/ko active IP Right Grant
- 2017-03-30 WO PCT/US2017/024976 patent/WO2017173056A1/en active Application Filing
- 2017-03-30 US US15/474,267 patent/US11135202B2/en active Active
- 2017-03-30 LT LTEP17716741.8T patent/LT3436074T/lt unknown
- 2017-03-30 DK DK17716741.8T patent/DK3436074T3/da active
- 2017-03-30 EA EA201891975A patent/EA036505B1/ru unknown
- 2017-03-30 HU HUE17716741A patent/HUE050601T2/hu unknown
- 2017-03-30 ES ES17716741T patent/ES2810303T3/es active Active
- 2017-03-30 KR KR1020217008677A patent/KR20210035339A/ko not_active Application Discontinuation
- 2017-03-30 JP JP2018550728A patent/JP6567781B2/ja active Active
- 2017-03-30 SG SG11201808453UA patent/SG11201808453UA/en unknown
- 2017-03-30 CN CN201780004281.XA patent/CN108289961A/zh active Pending
- 2017-03-30 SI SI201730344T patent/SI3436074T1/sl unknown
- 2017-03-30 EP EP20157908.3A patent/EP3677282A1/en active Pending
- 2017-03-30 AU AU2017244145A patent/AU2017244145B2/en active Active
- 2017-03-30 EP EP17716741.8A patent/EP3436074B1/en active Active
-
2018
- 2018-08-14 HK HK18110444.1A patent/HK1250945A1/zh unknown
- 2018-09-26 PH PH12018502058A patent/PH12018502058A1/en unknown
- 2018-09-27 IL IL262018A patent/IL262018A/en unknown
- 2018-09-28 MX MX2021004464A patent/MX2021004464A/es unknown
- 2018-10-05 ZA ZA2018/06644A patent/ZA201806644B/en unknown
-
2019
- 2019-07-31 JP JP2019141433A patent/JP2019203014A/ja active Pending
- 2019-09-23 AU AU2019236602A patent/AU2019236602A1/en not_active Abandoned
-
2020
- 2020-08-06 CY CY20201100732T patent/CY1123221T1/el unknown
- 2020-08-11 HR HRP20201261TT patent/HRP20201261T1/hr unknown
-
2021
- 2021-01-21 IL IL280327A patent/IL280327A/en unknown
- 2021-10-01 US US17/491,878 patent/US20220125767A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201261T1 (hr) | Spojevi tiazolidina za liječenje virusnih infekcija | |
| HRP20211906T1 (hr) | Dalargin za upotrebu u liječenju akutne respiratorne virusne infekcije | |
| HRP20220355T1 (hr) | Postupci za liječenje infekcija coronaviridae | |
| HRP20210724T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
| JP2016528301A5 (hr) | ||
| EA201991174A1 (ru) | Комбинация двух противовирусных препаратов для лечения гепатита c | |
| HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2015534562A5 (hr) | ||
| MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| PA8744101A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| JP2016513703A5 (hr) | ||
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| RU2012137097A (ru) | Способ и средство активации irf-3 для лечения и профилактики заболеваний | |
| BR112017009193A2 (pt) | método de tratamento de uma doença infecciosa, câncer, ou doença mieloproliferativa em um indivíduo; método de tratamento de uma doença mieloproliferativa em um indivíduo; e; interferon tipo i | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| RU2016101929A (ru) | Противовирусная эффективная фармацевтическая композиция | |
| RU2015131218A (ru) | Фармацевтическая композиция на основе будесонида для влажной ингаляции | |
| CN104257978A (zh) | 一种治疗***的中药组合物 | |
| Savić et al. | Pharmacotherapy of the common cold and influenza | |
| Samarasinghe et al. | Anti-Influenza Immunity In Allergic Asthma May Be Regulated By Eosinophils |